ProfileOfResearchers

151

TITLE: When Morphology Meets Somatic Mutations: The New Possible Scenario in Thyroid Fine-Needle Aspiration
AUTHORS: Esther Diana Rossi; Fernando Schmitt ;
PUBLISHED: 2016, SOURCE: ACTA CYTOLOGICA, VOLUME: 60, ISSUE: 2

INDEXED IN:

Scopus

WOS

CrossRef: 1

IN MY:

ORCID

152

TITLE: Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer Full Text
AUTHORS: Francisco Beca; Miguel Pereira; Jorge F Cameselle Teijeiro; Diana Martins; Fernando Schmitt ;
PUBLISHED: 2015, SOURCE: BMC CANCER, VOLUME: 15, ISSUE: 1

INDEXED IN:

Scopus

WOS

CrossRef: 21

IN MY:

ORCID

153

TITLE: Editorial
AUTHORS: Syrjänen, K; Vielh, P; Schmitt, F ; Nold, T;
PUBLISHED: 2015, SOURCE: Acta Cytologica, VOLUME: 59, ISSUE: 1

INDEXED IN:

Scopus

CrossRef: 4

IN MY:

ORCID

154

TITLE: EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer
AUTHORS: Merav Kedmi; Nir Ben Chetrit; Cindy Koerner; Maicol Mancini; Noa Bossel Ben Moshe; Mattia Lauriola; Sara Lavi; Francesca Biagioni; Silvia Carvalho; Hadas Cohen Dvashi; Fernando Schmitt ; Stefan Wiemann; Giovanni Blandino; Yosef Yarden;
PUBLISHED: 2015, SOURCE: SCIENCE SIGNALING, VOLUME: 8, ISSUE: 368

INDEXED IN:

Scopus

WOS

CrossRef: 48

IN MY:

ORCID

155

TITLE: Fine needle aspiration cytology of lobular breast carcinoma and its variants
AUTHORS: Mucha Dufloth, R; Xavier Júnior, JCC; Moraes Neto, FA; Janoti Dos Santos, K; Schmitt, F ;
PUBLISHED: 2015, SOURCE: Acta Cytologica, VOLUME: 59, ISSUE: 1

INDEXED IN:

Scopus

CrossRef: 5

IN MY:

ORCID

156

TITLE: Fine-needle aspiration cytology samples: A good source of material for evaluating biomarkers in breast cancer Full Text
AUTHORS: Schmitt, F ; Vielh, P;
PUBLISHED: 2015, SOURCE: Histopathology, VOLUME: 66, ISSUE: 2

INDEXED IN:

Scopus

CrossRef: 7

IN MY:

ORCID

157

TITLE: Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
AUTHORS: Gourgou Bourgade, S; Cameron, D; Poortmans, P; Asselain, B; Azria, D; Cardoso, F; A'Hern, R; Bliss, J; Bogaerts, J; Bonnefoi, H; Brain, E; Cardoso, MJ; Chibaudel, B; Coleman, R; Cufer, T; Dal Lago, L; Dalenc, F; De Azambuja, E; Debled, M; Delaloge, S; Filleron, T; Gligorov, J; Gutowski, M; Jacot, W; Kirkove, C; MacGrogan, G; Michiels, S; Negreiros, I; Offersen, BV; Penault P Llorca; Pruneri, G; Roche, H; Russell, NS; Schmitt, F ; Servent, V; Thuerlimann, B; Untch, M; van der Hage, JA; van Tienhoven, G; Wildiers, H; Yarnold, J; Bonnetain, F; Mathoulin Pelissier, S; Bellera, C; Dabakuyo Yonli, TS; ...More
PUBLISHED: 2015, SOURCE: ANNALS OF ONCOLOGY, VOLUME: 26, ISSUE: 5

INDEXED IN:

Scopus

WOS

IN MY:

ORCID

158

TITLE: Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
AUTHORS: Gourgou-Bourgade, S; Cameron, D; Poortmans, P; Asselain, B; Azria, D; Cardoso, F; A'Hern, R; Bliss, J; Bogaerts, J; Bonnefoi, H; Brain, E; M.J Cardoso; Chibaudel, B; Coleman, R; Cufer, T; Dal Lago, L; Dalenc, F; De Azambuja, E; Debled, M; Delaloge, S; Filleron, T; Gligorov, J; Gutowski, M; Jacot, W; Kirkove, C; MacGrogan, G; Michiels, S; Negreiros, I; B.V Offersen; Penault Llorca, F; Pruneri, G; Roche, H; N.S Russell; Schmitt, F ; Servent, V; Thürlimann, B; Untch, M; J.A van der Hage; van Tienhoven, G; Wildiers, H; Yarnold, J; Bonnetain, F; Mathoulin-Pélissier, S; Bellera, C; T.S Dabakuyo-Yonli; ...More
PUBLISHED: 2015, SOURCE: Annals of Oncology, VOLUME: 26, ISSUE: 12

INDEXED IN:

CrossRef: 29

IN MY:

ORCID

159